Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genentech Avastin study

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Overall survival data with Genentech's VEGF-inhibitor Avastin "suggest a stronger patient benefit than anticipated," firm reports at ASCO. Bevacizumab plus chemotherapy had a median survival of 20.3 months versus 15.6 months with chemo alone in a randomized Phase III study in previously untreated metastatic colorectal cancer patients. Hazard ratio for the 50% increased chance of survival was 0.65 (p=0.00003); the study was designed to detect a hazard ratio of 0.75, or a 33% increase in chance for survival. Avastin also met the secondary endpoints of progression-free survival, response rate and duration of response. Genentech "is currently discussing plans for the filing of a [BLA] with [FDA]"...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS002270

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel